Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00875342 · ClinicalTrials.gov registry record · NA

Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)

A NA study, sponsored by Weill Medical College of Cornell University.

Terminated
Registry status
NA
Development phase
41
Enrollment target

NCT00875342 is a NA study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 41 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00875342, a NA study, was terminated before completion, sponsored by Weill Medical College of Cornell University.

TERMINATED
Registry status
NA
Development phase
41 participants
Enrollment target

Study Summary

This study proposes to evaluate the effects of D-cycloserine (DCS) combined with cognitive-behavioral treatment with exposure therapy in a sample of patients who developed posttraumatic stress disorder (PTSD) as a consequence of various traumas (e.g., motor vehicle and accidents, burns and other injuries, combat, World Trade Center attack, etc.). In addition, this study hopes to determine whether a common human genetic single nucleotide polymorphism (SNP) in a growth factor, brain derived neurotrophic factor, BDNF SNP (Val66Met), predicts treatment response to PTSD. Patients living in areas that are not geographically proximal to the Weill-Cornell Medical Center New York City campus will receive cognitive behavioral therapy using telemedicine (videoconferencing technology). Overall, this study aims 1) to determine if subjects administered DCS show a significantly larger decrease in symptoms of PTSD as compared to those administered a placebo, 2) to determine if subjects administered DCS show a decrease in PTSD symptomatology significantly earlier (as measured by weeks) than those administered a placebo, 3) to determine if differences in symptomatology are evident at a 6-month follow-up and indicate long-term differences between groups, 4) to determine if the BDNF SNP predicts treatment response, 5)to determine if it is feasible and acceptable to provide imaginal exposure (IE) therapy for PTSD using videoconferencing technology.

Interventions

  • OTHER Placebo
  • DRUG DCS

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2008-05
Est. Completion 2018-02-28
Phase NA

What the Registry Record Tells You About NCT00875342

The ClinicalTrials.gov registry entry for NCT00875342 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00875342 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00875342 about?

NCT00875342 is a clinical study titled "Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)". This study proposes to evaluate the effects of D-cycloserine (DCS) combined with cognitive-behavioral treatment with exposure therapy in a sample of patients who developed posttraumatic stress disorder (PTSD) as a consequence of various traumas (e.g., motor vehicle and accidents, burns and other inj...

What is the current status of trial NCT00875342?

This trial is currently terminated. It is a NA study. The enrollment target is 41 participants. The study started on 2008-05. Estimated completion is 2018-02-28.

What interventions are being tested in trial NCT00875342?

The interventions under investigation include: Placebo (OTHER), DCS (DRUG).

Who is sponsoring clinical trial NCT00875342?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.